Revenue Breakdown
Composition ()
No data
Revenue Streams
IGC Pharma Inc (IGC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Tolling/White labeling service, accounting for 92.3% of total sales, equivalent to $251.00K. Another important revenue stream is Wellness and Lifestyle. Understanding this composition is critical for investors evaluating how IGC navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, IGC Pharma Inc maintains a gross margin of 51.83%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1518.85%, while the net margin is -953.40%. These profitability ratios, combined with a Return on Equity (ROE) of -83.34%, provide a clear picture of how effectively IGC converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, IGC competes directly with industry leaders such as BOLD and APUS. With a market capitalization of $27.89M, it holds a leading position in the sector. When comparing efficiency, IGC's gross margin of 51.83% stands against BOLD's N/A and APUS's N/A. Such benchmarking helps identify whether IGC Pharma Inc is trading at a premium or discount relative to its financial performance.
